Sunshine Lake Pharma Co., Ltd. is conducting a Phase 1 clinical trial to evaluate the pharmacokinetic similarity between its liraglutide injection (RD12014) and Novo Nordisk's Victoza®. The successful demonstration of bioequivalence could position RD12014 as a viable biosimilar in the growing GLP-1 receptor agonist market, which is driven by increasing prevalence of Type 2 diabetes and obesity. The competitive landscape includes established players like Novo Nordisk, Eli Lilly, and Sanofi, necessitating robust safety and efficacy data to gain market access. Given the trial's completion in November 2020, timely analysis of results will be critical for strategic planning and potential market entry.